A new analysis highlights the significant cardiovascular benefits of Novo Nordisk's obesity drug Wegovy, showing improvements regardless of weight loss amount. This challenges perceptions of GLP-1 drugs, suggesting they could be viewed more as heart or metabolic medications. Improved access and understanding are crucial, as these drugs could impact various chronic conditions like kidney disease. Acknowledging these connections could lead to more effective treatment approaches and better outcomes.
